Drug Profile
Imdusiran - Arbutus Biopharma
Alternative Names: AB-729; ARB 270729Latest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Arbutus Biopharma
- Developer Antios Therapeutics; Arbutus Biopharma; Assembly Biosciences
- Class Amides; Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; Hepatitis B virus replication inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 08 Jan 2024 Arbutus Biopharma plans a phase IIa AB-729-203 trial for Hepatitis (Combination therapy) in H1 of 2024
- 08 Jan 2024 Arbutus Biopharma plans a phase IIa trial in combination with an approved PD-L1 monoclonal antibody in H1 of 2024
- 04 Dec 2023 Arbutus Biopharma plans a phase II i-LIVER trial for Hepatitis B in December 2023 (SC) (NCT06154278)